Fortifying its orphan disease portfolio with gene therapies, Pfizer acquired US based private biotech Bamboo Therapeutics for a consolidated sum of up to US$645 M, including US$150 M upfront and US$495 M in contingent milestones. The agreement follows Pfizer’s previous acquisition in Q1 2016 of 22% of Bamboo’s shares for US$43 M. Pfizer will gain a phase I/II and three preclinical stage gene therapies for neurological and neuromuscular conditions, along with a manufacturing facility.